Three-way co-operation agreement to promote European interoperability
10.01.2020
EUROPE: A three-way agreement for administrative co-operation to promote technical interoperability, in particular for the transport of dangerous goods, has been signed by the Intergovernmental Organisation for International Carriage by Rail, the European Commission’s Directorate-General for Mobility & Transport and the EU Agency for Railways.

The agreement signed on September 29 is designed to be more flexible than their previous arrangement, which was signed following the EU’s accession to to the COTIF convention. It now runs indefinitely, rather than including an expiry date.

The new agreement:

  • sets out methods for exchanging information;
  • establishes a framework for interaction between OTIF and EU rules, so as to improve joint understanding;
  • defines continuous co-operation on the various technical registers;
  • strengthens co-ordination to ensure alignment of the railway laws of OTIF and the EU;
  • refers to the Joint Co-ordinating Group of Experts to ensure consistency between the Regulation concerning the International Carriage of Dangerous Goods by Rail (RID) and EU law.

The parties said the agreement enshrines the interdependence and close links between OTIF and the EU. It also reflects their wish to ‘improve, promote and facilitate’ international rail transport for ‘sustainable and greener’ development.

Topics
EU
Analytics on topic
Report
08.06.2020
Report
08.06.2020
European Economic Forecast (Summer 2020)
In a new European Economic Forecast, the European Commission expects a deeper recession and a slower recovery for the economy of the Union. However, the blow caused by the pandemic differs from country to country with some states and industries expected to recover faster due to internal factors.
Report
06.20.2019
Report
06.20.2019
The Europe Pharmaceutical Industry in Figures
The pharmaceutical industry is a key partner in Europe’s fight against disease, developing new treatments and cures for patients across Europe. It is imperative that Europe remains a competitive destination for medical research and development by maintaining, sustaining and developing a predictable, robust regulatory and innovation-supportive incentives environment.
Source: European Federation of Pharmaceutical Industries and Associations